US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Aimmune Therapeutics, a US-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its new chief medical officer. 23 June 2016
Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly-created position, at US pharma major Bristol-Myers Squibb, effective June 21, 2016. 22 June 2016
A former heavyweight at US health care giant Johnson & Johnson has been named in a key position with Biogen to lead the biotech company’s growth in development and manufacturing. 22 June 2016
Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017. 15 June 2016
Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016. 10 June 2016
The US District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen Therapeutics and Japan’s Takeda Pharmaceutical against Andrx and Actavis (now Allergan) companies. 10 June 2016
German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016. 7 June 2016
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Embattled drug company Valeant has named Tyco International executive Sam Eldessouky as corporate controller and a senior vice president as it tries rebuild its reputation after a string of controversies. 27 May 2016
US biotech Gilead Sciences has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy. 25 May 2016
US drugmaker Ariad Pharmaceuticals has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016. 25 May 2016
UK biotech Silence Therapeutics has announced a number of changes to its management as it positions itself as a leading RNA technology company. 25 May 2016
Olivier Brandicourt, chief executive of French pharma major Sanofi, announced today a number of changes to the company's executive committee. 23 May 2016
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016